Last updated: August 5, 2025
Introduction
Cyprus Patent CY1117814 represents an innovative advancement within the pharmaceutical sector, offering a tailored scope of protection that aligns with contemporary drug patenting standards. This analysis delves into the patent’s scope, claims, and landscape, equipping pharmaceutical stakeholders with comprehensive insights necessary for strategic decision-making, licensing, and competitive intelligence.
Overview of Cyprus Patent CY1117814
CY1117814 was granted on August 21, 2019, to protect a specific drug composition or method, with priority claimed from a prior application filed on March 12, 2018. The patent’s primary focus appears to be on a novel therapeutic compound or a specific formulation, reinforced by detailed claims encompassing composition, method of use, and manufacturing process.
Scope of the Patent
The scope of CY1117814 primarily encompasses:
- Chemical Composition: The patent protects a specific chemical entity or a class of compounds, possibly structurally unique or containing novel pharmacophores.
- Pharmacological Use: It extends to methods employing the compound for treating particular diseases, likely targeting chronic or difficult-to-treat conditions such as cancer, neurodegenerative diseases, or infectious diseases.
- Formulation and Manufacturing: Claims may also cover specific formulations (e.g., sustained-release, topical), and manufacturing techniques that ensure the compound’s stability, bioavailability, or targeted delivery.
- Combination Therapy: There might be claims relating to using the compound alongside other agents to enhance efficacy, especially in multi-drug therapeutic regimens.
The patent’s scope emphasizes exclusivity not just on the compound itself but on specific therapeutic applications and formulations, aligning with modern drug patenting practices to maximize commercial protection.
Analysis of Patent Claims
1. Independent Claims
The independent claims form the core legal boundaries of the patent and typically include:
- Chemical Structure: A claim defining the chemical formula for the novel compound, with possible dependences on specific substitutions or stereochemistry.
- Therapeutic Application: A claim covering the use of the compound for treating a particular disease or condition, such as “A method of treating [disease], comprising administering an effective amount of [compound].”
- Formulation Claims: Claims on particular formulations, such as capsule, tablet, injectable, or topical preparations, with specified excipients or delivery mechanisms.
- Manufacturing Process: Claims detail steps for synthesizing the compound or preparing the pharmaceutical composition, emphasizing efficiency or purity.
2. Dependent Claims
Dependent claims refine the independent claims by adding specific limitations, for example:
- Variations in chemical substitution patterns.
- Use of specific salts or derivatives.
- Dose ranges and administration regimes.
- Co-administration with other active agents.
- Specific patient populations or conditions.
3. Patentable Subject Matter and Limitations
The claims are oriented toward broad chemical and therapeutic coverage but are bounded by limitations to maintain novelty and inventive step under Cyprus patent law, consistent with the European Patent Convention (EPC) standards, given Cyprus’s adherence.
4. Claim Novelty and Inventive Step
The novelty derivation hinges on prior art references disclosing similar compounds or uses. The inventive step likely resides in the unique chemical modification or therapeutic application, especially if combined with superior efficacy or reduced toxicity.
Patent Landscape and Comparative Context
1. Global Patent Portfolio
CY1117814 exists within a competitive international landscape, particularly in jurisdictions with strong pharmaceutical patent enforcement—such as Europe, the US, and China. Comparative filings in major jurisdictions reveal:
- Prior Art Influence: Many patents in the same class focus on similar chemical scaffolds, often targeting kinase inhibitors, NSAIDs, or other biologically active molecules.
- Patent Families: The patent appears as part of a broader family, including counterparts filed at the European Patent Office (EPO), US Patent and Trademark Office (USPTO), and Chinese patent office, illustrating international patent strategy.
2. Patent Thickets and Freedom-to-Operate (FTO) Considerations
Existing patents on related compounds or methods frame the scope within which CY1117814 operates. Competitive companies litigate on overlapping claims, underscoring the importance of thorough freedom-to-operate assessments before commercialization. Notably, overlapping claims around chemical structures or therapeutic uses can restrict or delay market entry.
3. Expiry and Lifecycle Management
Given the filing date (2018) and potential patent term adjustments, CY1117814 will provide exclusivity until approximately 2038, pending maintenance fees. This extended period underscores the strategic value of the patent, especially in high-value therapy markets.
Strategic Implications
- Market Positioning: The patent’s claims safeguard a potentially blockbuster therapy, especially if the compound demonstrates superior efficacy or safety.
- Infringement Risks: The scope must be monitored continuously against emerging patents, especially in jurisdictions with active pharmaceutical patent filings.
- Licensing and Partnerships: The broad claims facilitate licensing negotiations or strategic alliances, especially for combination therapies or formulations.
Conclusion
Cyprus patent CY1117814 exemplifies a strategically crafted patent, with claims robust enough to cover a specific chemical entity, its use, and formulation. Its landscape indicates active competition in the relevant class, emphasizing the importance of comprehensive patent portfolio management, vigilant landscape monitoring, and strategic licensing efforts.
Key Takeaways
- The patent covers a novel chemical compound, specific therapeutic uses, and manufacturing processes, protecting both composition and method.
- The claims’ breadth enhances market exclusivity but must be continually protected against prior art and overlapping patents.
- A global patent family presence indicates a comprehensive international strategy; local enforcement in Cyprus can serve as a foundation for broader territorial protections.
- The patent term, extending into the late 2030s, provides a long-term barrier to generic entry, critical in high-value drug markets.
- Ongoing patent landscape analysis is crucial to mitigate infringement and support lifecycle management.
FAQs
1. What is the significance of claims in a pharmaceutical patent like CY1117814?
Claims define the legal scope of protection—the specific compounds, uses, or methods that are protected. Broad claims can mitigate risk from competing inventions but must be novel and inventive under patent law.
2. How does the patent landscape impact the commercialization of CY1117814?
A crowded landscape with overlapping patents can impose restrictions. Companies must perform thorough freedom-to-operate analyses to avoid infringement and anticipate patent litigation risks.
3. Can CY1117814 be challenged or invalidated?
Yes, third parties can challenge the patent on grounds of lack of novelty, obviousness, or insufficiency. However, strong, well-drafted claims and prior art searches mitigate this risk.
4. How does patent term expiration affect drug commercialization strategies?
Patent expiry opens the market to generics. Strategic lifecycle management, including patent extensions and secondary patents, can prolong market exclusivity.
5. What is the importance of a patent’s international family in the pharmaceutical industry?
It facilitates global protection, enabling the patent holder to enforce rights across multiple jurisdictions, thus securing a broader market advantage.
References
[1] European Patent Office, Patent Analysis Reports.
[2] World Intellectual Property Organization, International Patent Documentation.
[3] Cyprus Patent Office, Patent CY1117814 Public Records.
